Adicet Bio, Inc. (ACET) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adicet Bio, Inc. (ACET) Healthcare & Pipeline Overview

Adicet Bio, Inc., a biotechnology firm, pioneers allogeneic gamma delta T cell therapies targeting cancer. Their innovative approach leverages engineered T cells to enhance tumor targeting and immune response. With ADI-001 in Phase I trials for non-Hodgkin's lymphoma, Adicet is positioned within the competitive biotechnology landscape, focusing on novel cancer treatments.

What Is the Investment Thesis for ACET?

Adicet Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's allogeneic gamma delta T cell therapy platform holds promise for treating various cancers, with ADI-001 targeting non-Hodgkin's lymphoma in Phase I trials. Successful clinical trial outcomes and regulatory approvals could drive significant value. However, the company's market capitalization of $87.7M reflects the early stage of its pipeline and the inherent risks associated with biotechnology development. Key catalysts include the progression of ADI-001 through clinical trials and the advancement of ADI-002 into clinical studies. Potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. Investors should carefully consider the company's financial position, pipeline progress, and competitive landscape before investing.

Based on FMP financials and quantitative analysis

ACET Key Highlights

ADI-001 is currently in Phase I clinical study for the treatment of non-Hodgkin's lymphoma, representing a key milestone in the company's clinical development program.

• ADI-002 is undergoing preclinical studies for the treatment of various solid tumors, expanding the potential application of Adicet's gamma delta T cell platform.
• Adicet Bio's market capitalization is $0.07 billion, reflecting its early-stage development and growth potential.
• The company focuses on allogeneic therapies, aiming to provide off-the-shelf treatments that can be readily available to a broader patient population.
• Adicet Bio is based in Boston, Massachusetts, a hub of biotechnology innovation, facilitating collaborations and attracting top talent.

Who Are ACET's Competitors?

ACET is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ACET's Key Strengths?

Innovative allogeneic gamma delta T cell therapy platform.

• Potential for off-the-shelf cancer treatments.
• Lead product ADI-001 in Phase I clinical trials.
• Experienced management team.

What Are ACET's Weaknesses?

Early-stage development with limited clinical data.

• Reliance on successful clinical trial outcomes.
• High cash burn rate.
• Small market capitalization.

What Could Drive ACET Stock Higher?

ADI-001 Phase I clinical trial data readout.

• Advancement of ADI-002 into clinical studies.
• Strategic partnerships and collaborations.
• Development of next-generation gamma delta T cell therapies.

What Are the Key Risks for ACET?

Financial-distress signal — its Altman Z-Score of -5.75 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-80.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures.
• Regulatory hurdles.
• Competition from other cancer therapies.
• Need for additional funding.

What Are the Growth Opportunities for ACET?

• Expansion of ADI-001 Clinical Trials: Adicet Bio has the opportunity to expand the clinical trials for ADI-001 beyond Phase I, potentially targeting additional subtypes of non-Hodgkin's lymphoma or other hematological malignancies. The market for lymphoma treatments is estimated to reach $25 billion by 2028, providing a significant growth opportunity for Adicet if ADI-001 demonstrates efficacy and safety. Timeline for expansion is projected within the next 2-3 years, contingent on Phase I results.
• Advancement of ADI-002 into Clinical Studies: The preclinical development of ADI-002 for solid tumors presents a substantial growth opportunity. Solid tumors represent a larger market than hematological malignancies, and successful clinical translation of ADI-002 could significantly expand Adicet's addressable market. Preclinical studies are expected to conclude within the next 12-18 months, paving the way for clinical trials.
• Strategic Partnerships and Collaborations: Adicet Bio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. Collaborations can provide access to additional funding, expertise, and resources, enhancing Adicet's competitive position. The timeline for securing partnerships is ongoing, with potential deals expected within the next 1-2 years.
• Development of Next-Generation Gamma Delta T Cell Therapies: Adicet Bio can invest in the development of next-generation gamma delta T cell therapies with enhanced targeting capabilities or improved persistence. This could involve incorporating novel technologies or engineering approaches to further optimize the therapeutic potential of its platform. Research and development efforts are projected to yield new candidates within the next 3-5 years.
• Expansion into New Geographic Markets: Adicet Bio has the potential to expand its operations into new geographic markets, such as Europe and Asia, to broaden its reach and access a larger patient population. This would require establishing clinical trial sites and regulatory pathways in these regions. Market entry into Europe and Asia is projected within the next 3-5 years, contingent on regulatory approvals and market access considerations.

What Are ACET's Competitive Advantages?

• Proprietary allogeneic gamma delta T cell therapy platform.
• Patents protecting its engineered T cell technologies.
• Clinical data demonstrating efficacy and safety.
• Expertise in gamma delta T cell biology and engineering.

What Does ACET Do?

Adicet Bio, Inc., founded with the mission of revolutionizing cancer treatment, is a biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies. The company's core technology centers around engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This innovative approach aims to enhance selective tumor targeting, facilitate both innate and adaptive anti-tumor immune responses, and improve the persistence of therapeutic effects in patients. Adicet's lead product candidate, ADI-001, is currently undergoing a Phase I clinical study for the treatment of non-Hodgkin's lymphoma, representing a significant milestone in the company's clinical development program. In addition to ADI-001, Adicet is also advancing ADI-002, which is in preclinical development for the treatment of various solid tumors, expanding the potential application of its gamma delta T cell platform. Based in Boston, Massachusetts, Adicet Bio is strategically located within a hub of biotechnology innovation, fostering collaborations and attracting top talent to drive its research and development efforts. The company's focus on allogeneic therapies aims to provide off-the-shelf treatments that can be readily available to a broader patient population, addressing a critical need in cancer care.

What Products and Services Does ACET Offer?

• Discovers and develops allogeneic gamma delta T cell therapies.
• Engineers gamma delta T cells with chimeric antigen receptors (CARs).
• Develops T cell receptor-like antibodies to enhance tumor targeting.
• Facilitates innate and adaptive anti-tumor immune response.
• Enhances persistence for durable activity in patients.
• Conducts Phase I clinical study for ADI-001 in non-Hodgkin's lymphoma.
• Engages in preclinical studies for ADI-002 for solid tumors.

How Does ACET Make Money?

• Develops and patents novel allogeneic gamma delta T cell therapies.
• Conducts preclinical and clinical research to demonstrate safety and efficacy.
• Seeks regulatory approvals from agencies like the FDA.
• Potentially commercializes therapies directly or through partnerships.

What Industry Does ACET Operate In?

Adicet Bio operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory scrutiny. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Adicet's focus on allogeneic gamma delta T cell therapies positions it within the emerging field of cell-based immunotherapies. Key competitors include companies developing CAR-T cell therapies and other immunotherapeutic approaches. The success of Adicet Bio will depend on its ability to demonstrate clinical efficacy, navigate regulatory pathways, and secure sufficient funding to support its research and development efforts.

Who Are ACET's Key Customers?

• Patients with cancer, particularly non-Hodgkin's lymphoma and solid tumors.
• Hospitals and oncology clinics that administer the therapies.
• Pharmaceutical companies that may partner with Adicet for commercialization.

How Adicet Bio, Inc. Is Valued

Adicet Bio, Inc. carries a market capitalization of $87.7M, placing it in the micro-cap category. Relative to its peer group, ACET's quantitative score of 26/100 is below the peer average of 76/100.

Company Profile

Adicet Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Chen Schor. ACET has traded publicly since 2018.

Return on equity for Adicet Bio, Inc. stands at -80.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.3%, showing how much profit it generates from its asset base. A current ratio of 7.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -114.4%, the inverse of the P/E and a quick read on earnings relative to price.

Adicet Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.75 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Adicet Bio, Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-7.45. The estimate reflects 6 contributing analysts.

ACET Financials

ACET Latest News

ACET Analyst Consensus

ACET MoonshotScore

Latest Adicet Bio, Inc. Analysis

Adicet Bio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources